医学
肿瘤科
转移性乳腺癌
化疗
内科学
总体生存率
回顾性队列研究
乳腺癌
癌症
作者
Laura Jean Havrilesky,Maureen T. Reiner,Phuong Khanh H Morrow,Holly Howe Watson,Jeffrey Crawford
标识
DOI:10.1016/j.critrevonc.2014.10.006
摘要
Studies have shown that in the curative setting patients with cancer receiving chemotherapy at higher relative dose intensity (RDI) had better clinical outcomes than those receiving treatment at lower RDI. However, the impact of RDI in advanced/metastatic disease remains unclear. A review of the literature was performed to evaluate the relationship between RDI and survival in patients with metastatic lung, breast, or ovarian cancer receiving chemotherapy. Few studies attempted to specifically associate RDI with survival in a systematic way. Findings from studies that analyzed overall survival with a prespecified RDI threshold support the emerging perception that maintaining an RDI ≥ 85% has a favorable impact on survival. Nonetheless, these studies were limited by their retrospective nature. More studies are needed to further evaluate the impact of maintaining planned chemotherapy dose intensity on outcomes in metastatic solid tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI